Improving BP control with combined renin-angiotensin system blockade and thiazide diuretics in hypertensive patients with diabetes mellitus or kidney disease

American Journal of Cardiovascular Drugs

Volumn 8, Issue 1, 2008, Pages 9-14

  Palmer, Biff F ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ACE inhibitors, therapeutic use; Angiotensin receptor antagonists, therapeutic use; Diabetes mellitus; Hypertension, treatment; Kidney disorders; Losartan hydrochlorothiazide, therapeutic use; Olmesartan medoxomil hydrochlorothiazide, therapeutic use

Indexed keywords

ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; OLMESARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANGIONEUROTIC EDEMA; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; COUGHING; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; INSULIN SENSITIVITY; KIDNEY DISEASE; KIDNEY FAILURE; METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 39749200067     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200808010-00002     Document Type: Review

References (59)

1. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004; 44 (4): 398-404
2. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49 (1): 69-75
3. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42 (6): 1206-52
4. U.S. Department of Health and Human Services. Healthy people 2010: understanding and improving health. 2nd ed. Washington, DC: U.S. Government Printing Office, 2000
5. Julius S, Kjeldsen SE, Weber M, et al., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363 (9426): 2022-31
6. Ritz E. Heart and kidney: fatal twins? Am J Med 2006; 119 (5 Suppl. 1): S31-9
7. Miller NH, Hill M, Kottke T. et al., for the Expert Panel on Compliance - American Heart Association. The multilevel compliance challenge: recommendations for a call to action. A statement for health care professionals. Circulation 1997; 95 (4): 1085-90
8. Okonofua EC, Simpson KN, Jesri A, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006; 47 (3): 345-51
9. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002; 4 (6): 393-404
10. Phillips L, Branch W, Cook C, et al. Clinical inertia. Ann Int Med 2001; 135: 825-34
11. Arauz-Pacheco C, Parrott MA, Raskin P, et al. Hypertension management in adults with diabetes. Diabetes Care 2004; 27 Suppl. 1: S65-7
12. Douglas JG, Bakris GL, Epstein M, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003; 163 (5): 525-41
13. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002; 347 (16): 1256-61
14. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165 (12): 1410-9
15. Whelton PK, Barzilay J, Cushman WC, et al., for the ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165 (12) 1401-9
16. Black H, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in non-diabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the ALLHAT study. Diabetes Care. Epub 2007 Nov 13
17. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286 (5): H1597-602
18. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7
19. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167-74
20. Reaven GM. Relationship between insulin resistance and hypertension. Diabetes Care 1991; 14 Suppl. 4: 33-8
21. Messerli FH, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004; 22: 1845-7
22. Mason JM, Dickinson HO, Nicolson DJ, et al. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005; 23: 1777-81
23. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3-10
24. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43 (5): 963-9
25. Zillich A, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quatitative review. Hypertension 2006; 48: 219-24
26. Cutler J. Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key. Hypertension 2006; 48: 198-200
27. ATP channels in pancreatic beta cells underlies a spectrum of diabetic phenotypes. Diabetes 2006; 55: 2957-64
28. Barzilay J, Cutler J, Davis B. Antihypertensive medications and risk of diabetes mellitus. Curr Opin Nephrol Hypertens 2007; 16: 256-60
29. Viberti G, Wheeldon NM, on behalf of the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106 (6): 672-8
30. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329 (20): 1456-62
31. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60
32. Parving H-H, Lehnert H, Brochner-Mortensen J, et al., for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12): 870-8
33. Brenner B, Cooper M, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9
34. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355 (9200): 253-9
35. Dahlöf B, Devereux RB, Kjeldsen SE, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359 (9311): 995-1003
36. Suissa S, Hutchison T, Brophy J, et al. Ace-inhibitor use and the long term risk of renal failure in diabetes. Kidney Intl 2006; 69: 913-9
37. Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol 2007; 27: 287-93
38. Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2000; 2 (4): 402-11
39. Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46 (5): 821-6
40. Kjeldsen SE, Os I, Høieggen A, et al. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005; 5 (1): 17-22
41. Mimran A, Weir MR. Angiotensin-receptor blockers and diuretics: advantages of combination. Blood Press 2005; 14 (1): 6-11
42. Mogensen CE. New concepts in blood pressure-lowering management in diabetic patients: the case for early ACE inhibitor combination therapy with diuretics. J Hum Hypertens 2005; 19 Suppl. 1: S15-20
43. Sica DA. Pharmacotherapy review: angiotensin receptor antagonists. J Clin Hypertens 2005; 7 (11): 681-4
44. Hanes DS, Weir MR. Renal protection in chronic kidney disease. In: Oparil S, Weber MA, editors. Hypertension. 2nd ed. Philadelphia (PA): Elsevier Inc., 2005
45. de Zeeuw D, Remuzzi G, Parving H-H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65 (6): 2309-20
46. Esnault VL, Ekhlas A, Delcroix C, et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16 (2): 474-81
47. Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13 (7): 1682-5
48. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326 (7404): 1427
49. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103 (6): 904-12
50. Salerno CM, Demopoulos L, Mukherjee R, et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004; 6 (11): 614-20
51. Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005; 27 (7): 1013-21
52. Mallion JM, Carretta R, Trenkwalder P, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Press Suppl 2003; 1: 36-43
53. Sachse A, Verboom CN, Jäger B. Efficacy of eprosartan in combination with HCTZ in patients with essential hypertension. J Hum Hypertens 2002; 16 (3): 169-76
54. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17 (3): 252-9
55. Lacourcière Y, Poirier L. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am J Hypertens 2003; 16 (12): 1036-42
56. de Pablos-Velasco PL, Pazos, et al. Losartan titration versus diuretic combination in type 2 diabetic patients. J Hypertens 2002; 20 (4): 715-9
57. Pool J, Glazer R, Weinberger M, et al. Comparison of valsartan/ hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 2007 Jan; 29 (1): 61-73
58. Ridker PM, Danielson E, Rifai N, et al. for the Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report 2 of the Val-MARC trial. Hypertension 2006; 48 (1): 73-9
59. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351 (6): 585-92